Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 141, Issue 1, 2016, Pages 43-48

  Myers, Andrea P ^a   Filiaci, Virginia L ^b   Zhang, Yuping ^c   Pearl, Michael ^d   Behbakht, Kian ^e   Makker, Vicky ^f   Hanjani, Parviz ^g   Zweizig, Susan ^h   Burke, James J ⁱ   Downey, Gordon ^j   Leslie, Kimberly K ^c   Van Hummelen, Paul ^a   Birrer, Michael J ^k   Fleming, Gini F ^l  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NRG Oncology Statistics and Data Management Center   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d Stony Brook School of Dental Medicine   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g ABINGTON MEMORIAL HOSPITAL   (United States)

^h University of Massachusetts   (United States)

ⁱ MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j Gynecologic Oncology of West Michigan   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MEGESTROL ACETATE; TAMOXIFEN; TEMSIROLIMUS; AKT1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE B; PTEN PROTEIN, HUMAN; RAPAMYCIN; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN;

AKT1 GENE; ARTICLE; CANCER PATIENT; CTNNB1 GENE; DNA ISOLATION; DRUG EFFICACY; ENDOMETRIUM CANCER; FBXW7 GENE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MUTATION RATE; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; NF1 GENE; ONCOGENE; ONCOGENE K RAS; PHASE 2 CLINICAL TRIAL (TOPIC); PIK3CA GENE; PIK3R1 GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PTEN GENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TREATMENT RESPONSE; TSC1 GENE; TSC2 GENE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; ENDOMETRIAL NEOPLASMS; GENETICS; MORTALITY; MUTATION; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MEGESTROL ACETATE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIROLIMUS; TAMOXIFEN; TUMOR SUPPRESSOR PROTEINS;

EID: 84961786628     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.02.025     Document Type: Article

References (37)

1. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J. Clin. 65 1 2015 5 29
2. G.F. Fleming Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant J. Clin. Oncol. 25 20 2007 2983 2990
3. C.C. Dibble, and L.C. Cantley Regulation of mTORC1 by PI3K signaling Trends Cell Biol. 25 9 2015 545 555
4. A. Dutt, H.B. Salvesen, H. Greulich, W.R. Sellers, R. Beroukhim, and M. Meyerson Somatic mutations are present in all members of the AKT family in endometrial carcinoma Br. J. Cancer 101 7 2009 1218 1219 author reply 20-1
5. M.E. Urick, M.L. Rudd, A.K. Godwin, D. Sgroi, M. Merino, and D.W. Bell PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer Cancer Res. 71 12 2011 4061 4067
6. H. Tashiro, M.S. Blazes, R. Wu, K.R. Cho, S. Bose, S.I. Wang, and et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies Cancer Res. 57 18 1997 3935 3940
7. J.I. Risinger, A.K. Hayes, A. Berchuck, and J.C. Barrett PTEN/MMAC1 mutations in endometrial cancers Cancer Res. 57 21 1997 4736 4738
8. M.L. Rudd, J.C. Price, S. Fogoros, A.K. Godwin, D.C. Sgroi, M.J. Merino, and et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas Clin. Cancer Res. 17 6 2011 1331 1340
9. K. Shoji, K. Oda, S. Nakagawa, S. Hosokawa, G. Nagae, Y. Uehara, and et al. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas Br. J. Cancer 101 1 2009 145 148
10. Network. TCGAR Integrated genomic characterization of endometrial carcinoma Nature 497 2013 67 73
11. N. Colombo, D.S. McMeekin, P.E. Schwartz, C. Sessa, P.A. Gehrig, R. Holloway, and et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial Br. J. Cancer 108 5 2013 1021 1026
12. G.F. Fleming, V.L. Filiaci, B. Marzullo, R.J. Zaino, S.A. Davidson, M. Pearl, and et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study Gynecol. Oncol. 132 3 2014 585 592
13. A.M. Oza, L. Elit, M.S. Tsao, S. Kamel-Reid, J. Biagi, D.M. Provencher, and et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group J. Clin. Oncol. 29 24 2011 3278 3285
14. A.M. Oza, S. Pignata, A. Poveda, M. McCormack, A. Clamp, B. Schwartz, and et al. Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma J. Clin. Oncol. 2015
15. I. Ray-Coquard, L. Favier, B. Weber, C. Roemer-Becuwe, P. Bougnoux, M. Fabbro, and et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO Br. J. Cancer 108 9 2013 1771 1777
16. B.M. Slomovitz, Y. Jiang, M.S. Yates, P.T. Soliman, T. Johnston, M. Nowakowski, and et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma J. Clin. Oncol. 33 8 2015 930 936
17. B.M. Slomovitz, K.H. Lu, T. Johnston, R.L. Coleman, M. Munsell, R.R. Broaddus, and et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma Cancer 116 23 2010 5415 5419
18. D. Tsoref, S. Welch, S. Lau, J. Biagi, K. Tonkin, L.A. Martin, and et al. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer Gynecol. Oncol. 135 2 2014 184 189
19. H.J. Mackay, E.A. Eisenhauer, S. Kamel-Reid, M. Tsao, B. Clarke, K. Karakasis, and et al. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer Cancer 120 4 2014 603 610
20. L.A. Meyer, B.M. Slomovitz, B. Djordjevic, S.N. Westin, D.A. Iglesias, M.F. Munsell, and et al. The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer Int. J. Gynecol. Cancer 24 4 2014 713 717
21. O. Tredan, I. Treilleux, Q. Wang, N. Gane, D. Pissaloux, N. Bonnin, and et al. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study Target. Oncol. 8 4 2013 243 251
22. N. Wagle, B.C. Grabiner, E.M. Van Allen, A. Amin-Mansour, A. Taylor-Weiner, M. Rosenberg, and et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer N. Engl. J. Med. 371 15 2014 1426 1433
23. G. Iyer, A.J. Hanrahan, M.I. Milowsky, H. Al-Ahmadie, S.N. Scott, M. Janakiraman, and et al. Genome sequencing identifies a basis for everolimus sensitivity Science 338 6104 2012 221
24. M.A. DePristo, E. Banks, R. Poplin, K.V. Garimella, J.R. Maguire, C. Hartl, and et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data Nat. Genet. 43 5 2011 491 498
25. K. Cibulskis, M.S. Lawrence, S.L. Carter, A. Sivachenko, D. Jaffe, C. Sougnez, and et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples Nat. Biotechnol. 31 3 2013 213 219
26. C.J. Clopper, and E.S. Pearson The use of confidence or fiducial limits illustrated in the case of the binomial Biometrika 26 1934 404 413
27. D.J. Venzon, and S.H. Moolgavkar A method for computing profile-likelihood based confidence intervals Appl. Stat. 37 1988 87 94
28. Cancer Genome Atlas Research Network, C. Kandoth, N. Schultz, A.D. Cherniack, R. Akbani, Y. Liu, and et al. Integrated genomic characterization of endometrial carcinoma Nature 497 7447 2013 67 73
29. G.F. Fleming, V.L. Filiaci, R.C. Bentley, T. Herzog, J. Sorosky, L. Vaccarello, and et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study Ann. Oncol. 15 8 2004 1173 1178
30. S.Y. Han, H. Kato, S. Kato, T. Suzuki, H. Shibata, S. Ishii, and et al. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay Cancer Res. 60 12 2000 3147 3151
31. D.J. Kwiatkowski, V.H. Whittemore, and E.A. Thiele Tuberous Sclerosis Complex: Genes, Clinical Features, and Therapeutics 2010 Wiley-Blackwell Weinheim xxi, 409 pp.
32. J.J. Bissler, J.C. Kingswood, E. Radzikowska, B.A. Zonnenberg, M. Frost, E. Belousova, and et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial Nephrol. Dial. Transplant. 2015
33. D.N. Franz, E. Belousova, S. Sparagana, E.M. Bebin, M. Frost, R. Kuperman, and et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial Lancet 381 9861 2013 125 132
34. M. Hoogeveen-Westerveld, R. Ekong, S. Povey, K. Mayer, N. Lannoy, F. Elmslie, and et al. Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex Hum. Mutat. 34 1 2013 167 175
35. M. Hoogeveen-Westerveld, C. Exalto, A. Maat-Kievit, A. van den Ouweland, D. Halley, and M. Nellist Analysis of TSC1 truncations defines regions involved in TSC1 stability, aggregation and interaction Biochim. Biophys. Acta 1802 9 2010 774 781
36. Y. Liu, L. Patel, G.B. Mills, K.H. Lu, A.K. Sood, L. Ding, and et al. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma J. Natl. Cancer Inst. 106 9 2014
37. A. Myers, W.T. Barry, M.S. Hirsch, U. Matulonis, and L. Lee Beta-catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers Gynecol. Oncol. 134 2 2014 426 427